Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

e neutropenia (20%), and cardiac failure (3%).

"Although there are a number of treatment regimens that have been studied as salvage therapies in patients with relapsed aggressive NHL, few have demonstrated a high proportion of complete responses and many of the remissions achieved are of relatively short duration," said Jack W. Singer, M.D. Chief Medical Officer at CTI. "Patients who have completed a course of CHOP therapy are unable to be retreated with the same regimen due to the potential for severe heart toxicity when the lifetime limit of doxorubicin is exceeded.  Pixantrone has substantially less cardiotoxicity than doxorubicin in animal models and was found to be adequately tolerated in patients treated with prior doxorubicin in phase I trials.  The present study suggests that use of pixantrone with CPOP not only offers a high response rate, but in some patients these responses had impressive durability.  Four patients in the study had unmaintained remissions of between 4+ and 6+ years duration following CPOP, which is highly unusual in the setting of treating relapsed disease. The opportunity to re-challenge patients with a CHOP-like regimen, using pixantrone instead of doxorubicin after relapse from initial therapy with CHOP indicates that pixantrone-based regimens may represent a new approach to managing relapsed aggressive NHL. A Phase III clinical trial with pixantrone in this setting has recently been initiated, the PIX-R TRIAL™."

About Pixantrone and the CPOP Regimen

This trial examines the safety and potential efficacy of pixantrone (CPOP) when it is used in place of doxorubicin in the CHOP regimen for patients with relapsed aggressive NHL who had failed at least one prior treatment.  

Patients received up to six cycles of CPOP therapy. Cycles were every 21 days.  The phase I dose level was 80-180 mg/m for phase I, and the phase II recommended dose was 150 mg/m2. For both phases, dosing
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Nov. 28, 2014 /CNW Telbec/ - Ergoresearch Ltd « Ergoresearch ... of Mrs. Dominique Boudreau who will hold ... Mrs. Dominique Boudreau was acting as corporate ... similar duties for more than seven years for Laboratoire ... January 2013.  Mrs. Boudreau replaces Mr. Greco who was ...
(Date:11/28/2014)... Kan. , Nov. 28, 2014 Aratana ... company focused on the licensing or acquisition, development and ... other companion animals, today announced that it will present ... Conference, to be held December 2-3, 2014, at the ... . Steven St. Peter , ...
(Date:11/28/2014)... 28, 2014 Alimera Sciences, Inc. (NASDAQ: ... that specializes in the research, development and commercialization ... Securities Purchase Agreement with Deerfield Management and certain ... will issue shares of preferred stock to Deerfield ... million upon the satisfaction of certain closing conditions. ...
Breaking Medicine Technology:Ergoresearch announces the appointment of its new Vice Président Finance 2Ergoresearch announces the appointment of its new Vice Président Finance 3Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3
... 5, 2011 Mylan Inc. (Nasdaq: MYL ) today ... of the NASDAQ OMX Group Inc. (Nasdaq: NDAQ ), ... due 2012 from the Nasdaq Capital Market, on which the notes ... of trading on January 28, 2011. The notes will continue to ...
... and older falls every 2.3 seconds in the U.S., and according ... cause of fatal injury in this age group. They are ... for trauma.  The growing ranks of Americans 65 and older - ... 2050 - have inspired a new technology solution that allows the ...
Cached Medicine Technology:Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 3
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently introduced ... Jeffrey Epstein is excited to offer patients the ... the site is uniquely designed for easing viewing on ... of all prospective rhinoplasty patients research upcoming procedures online. ... with smartphones, tablets, and laptops, as well as the ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Written and narrated ... Brook Forest Voices releases the “The Happiest Man In ... a compelling account of how and why Project C.U.R.E. came ... by his mother Josie and the Reverend Richard W. Jackson, ... the age of 30, but realized that he wasn’t happy. ...
(Date:11/28/2014)... Not only is the Éminence Organic ... petroleum, parabens and other cancer-causing agents, but they are ... and awareness programs that help in the fight against ... raised an incredible, record-breaking contribution of $30,000 through participation ... the Sweet Red Rose Whip Moisturizer and the company’s ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Mabel’s ... stuff kids lose® and an award-winning company established by ... Ellis, Cynthia Esp, and Tricia Mumby have been honored ... were recognized with the PROFIT Award for Excellence in ... Cynthia Esp, and Tricia Mumby) accepted the award on ...
(Date:11/28/2014)... Lice Troopers Lice Removal Service is pleased to ... lice service for moms in Miami-Dade County. Lice Troopers is ... on Pone De-leon Blvd in Miami. The company currently ... Miami-Dade & Broward. Lice Troopers is the only Lice Clinic ... been treating families for several years. , Lice Troopers estimate ...
Breaking Medicine News(10 mins):Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2
... ... for dentists with advanced clinical training announced. , ... Seattle, WA (PRWEB) June 23, 2009 -- Big Case Marketing, the global ... for large cases and Dental Idea Lab, a Boston based coaching and consulting firm for ...
... ... and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, evaluates and ... price reduction in the cost of liquid culture testing for TB (Tuberculosis). , ... Oxford, UK and Geneva, ...
... SAN DIEGO, June 22 CetylMax, LLC and Flexadren, ... Cetylated Fatty Acids (CFA,s) products aiding in joint support ... Board: IAGX), the manufacturer of Celadrin, did not prevail ... the nature and outcome of the Federal litigation between ...
... inhibitor of tumor metastasis made by tumor cells, one that ... were published in the online Early Edition of the ... week of June 22. Metastasisthe migration of cancer ... leading causes of death from cancer, and there is no ...
... WASHINGTON, June 22 The Lupus Foundation of America ... studies on lupus, an unpredictable and potentially fatal autoimmune ... lupus and adult stem cell transplantation. The purposes of ... research in humans as a treatment for lupus and ...
... , , Personalized Medicine Meeting Elicits Varying Perspectives ... Drug Administration,s (FDA,s) ability to regulate genetic testing is problematic, ... , Three-quarters of the attendees at a colloquium ... Institute (FDLI) and the American Association for the Advancement of ...
Cached Medicine News:Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 3Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 2Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 3Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 4Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 2Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 3Health News:Potent metastasis inhibitor identified 2Health News:Lupus Foundation of America Seeks Proposals for Research Studies on Childhood Lupus and Stem Cell Transplantation 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 3
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
Semi-Rigid Ureteroscope...
... ACMI DUR-8 Elite's 8.7 Fr shaft reaches ... comparable scope providing complete intrarenal access, ... smooth, lubricious outer covering and working channel ... And its patented torque-stable shaft construction, tight-bend ...
Medicine Products: